Acute Exacerbation of Pulmonary Fibrosis And Complications of Noninvasive Positive Pressure Ventilation: A Case Report

International Journal of Medical Science

© 2020 by SSRG - IJMS Journal

Volume 7 Issue 12

Year of Publication : 2020

Authors : Chukwuemeka A. Umeh, Ankit Dubey, Mohammad Yousuf, Stella Onyi, Hycienth Ahaneku

10.14445/23939117/IJMS-V7I12P104

How to Cite?

Chukwuemeka A. Umeh, Ankit Dubey, Mohammad Yousuf, Stella Onyi, Hycienth Ahaneku, "Acute Exacerbation of Pulmonary Fibrosis And Complications of Noninvasive Positive Pressure Ventilation: A Case Report," SSRG International Journal of Medical Science, vol. 7,  no. 12, pp. 14-17, 2020. Crossref, https://doi.org/10.14445/23939117/IJMS-V7I12P104

Abstract:

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic interstitial lung disease of unknown cause, often associated with characteristic radiologic and/or histopathologic pattern and occurs primarily in older adults. Acute exacerbation of IPF (AE-IPF) usually has poor outcomes, and mechanical ventilation has not been shown to benefit AE-IPF patients. Noninvasive ventilation (NIV) has attracted attention to avoid intubation in acute respiratory failure in AE-IPF.
Case report
We present a case of a 49-year-old male with AE-IPF placed on NIV that developed bilateral pneumothorax and pneumomediastinum as complications from NIV, who had to be intubated after being taken off NIV and eventually passed away.
Conclusion
Our case report highlights that NIV is also associated with complications and mortality in AE-IPF. AE-IPF patients and family should be informed of the very poor prognosis and the available options for treatment of respiratory failure in IPF, including the possible benefits and complications, and a joint decision should be made ahead of time on what to do in respiratory failure based on the goal of care.

Keywords:

Acute exacerbation of idiopathic pulmonary fibrosis, Noninvasive ventilation, pneumothorax, pneumomediastinum, case report

References:

[1] Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al.; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement. Idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med, 183 (2011), 788–824.
[2] Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. New England Journal of Medicine. 10;378(19)(2018), 1811-23.
[3] Yokoyama T, Kondoh Y, Taniguchi H, Kataoka K, Kato K, Nishiyama O, Kimura T, Hasegawa R, Kubo K. Noninvasive ventilation in acute exacerbation of idiopathic pulmonary fibrosis. Internal Medicine., 49(15)(2010), 1509-14,.
[4] Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, Lee JS, Maher TM, Wells AU, Antoniou KM, Behr J. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. American journal of respiratory and critical care medicine.,194(3) (2016 ), 265-75.
[5] Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors, and outcome. Eur RespirJ; 37(2011), 356–363.
[6] Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C; IPFnet investigators. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res.,(2013), 14:73.
[7] Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, Lasky JA, Loyd JE, Noth I, Olman MA, et al., Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med; 176 (2007), 636–643.
[8] Johannson KA, Vittinghoff E, Lee K, Balmes JR, Ji W, Kaplan GG, Kim DS, Collard HR. Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure. Eur Respir J; 43 (2014), 1124–1131.
[9] Mura M, Porretta MA, Bargagli E, Sergiacomi G, Zompatori M, Sverzellati N, Taglieri A, Mezzasalma F, Rottoli P, Saltini C, et al. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J., 40 (2012), 101–109.
[10] Ohshima S, Ishikawa N, Horimasu Y, Hattori N, Hirohashi N, Tanigawa K, Kohno N, Bonella F, Guzman J, Costabel U. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis. Respir Med., 108 (2014), 1031–1039.
[11] Schupp JC, Binder H, Jäger B, Cillis G, Zissel G, Müller-Quernheim J, Prasse A. Macrophage activation in acute exacerbation of idiopathic pulmonary fibrosis. Plos One., (2015),10:e0116775.
[12] Kondoh Y, Taniguchi H, Katsuta T, Kataoka K, Kimura T, Nishiyama O, Sakamoto K, Johkoh T, Nishimura M, Ono K, et al. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis., 27 (2010), 103–110.
[13] Kishaba T, Tamaki H, Shimaoka Y, Fukuyama H, Yamashiro S. Staging acute exacerbation in patients with idiopathic pulmonary fibrosis. Lung., 192 (2014), 141–149.
[14] Kondoh Y, Taniguchi H, Ebina M, Azuma A, Ogura T, Taguchi Y, Suga M, Takahashi H, Nakata K, Sugiyama Y, et al. Risk factors for acute exacerbation of idiopathic pulmonary fibrosis: an extended analysis of pirfenidone trial in Japan. Respir Investig., 53 (2015), 271–278.
[15] Reichmann WM, Yu YF, Macaulay D, Wu EQ, Nathan SD. Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis. BMC Pulm Med., (2015), 15:167.
[16] Mason DP, Brizzio ME, Alster JM, McNeill AM, Murthy SC, Budev MM, Mehta AC, Minai OA, Pettersson GB, Blackstone EH. Lung transplantation for idiopathic pulmonary fibrosis. Ann Thorac Surg, 84(2007), 1121–1128.
[17] Keating D, Levvey B, Kotsimbos T, Whitford H, Westall G, Williams T, Snell G. Lung transplantation in pulmonary fibrosis: challenging early outcomes counterbalanced by surprisingly good outcomes beyond 15 years. Transplant Proc., 41 (2009), 289–291.
[18] Trudzinski FC, Kaestner F, Schäfers HJ, Fähndrich S, Seiler F, Böhmer P, Linn O, Kaiser R, Haake H, Langer F, Bals R. Outcome of patients with interstitial lung disease treated with extracorporeal membrane oxygenation for acute respiratory failure. American journal of respiratory and critical care medicine.,193(5)(2016), 527-33.
[19] Lafarge M, Mordant P, Thabut G, Brouchet L, Falcoz PE, Haloun A, Le Pimpec-Barthes F, Maury JM, Reynaud-Gaubert M, Saint-Raymond C, Sage E. Experience of extracorporeal membrane oxygenation as a bridge to lung transplantation in France. The Journal of Heart and Lung Transplantation.32(9) (2013), 905-13.